Cargando…
Mechanisms of resistance to RAF inhibitors in melanoma
The recent RAF inhibitor trial with PLX4032/RG7204 in late-stage mutant B-RAF melanoma patients has been lauded as a success story for personalized cancer therapy since short-term clinical responses were observed in the majority patients. However, initial responses were followed by subsequent tumor...
Autores principales: | Aplin, Andrew E., Kaplan, Fred M., Shao, Yongping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3156870/ https://www.ncbi.nlm.nih.gov/pubmed/21593776 http://dx.doi.org/10.1038/jid.2011.147 |
Ejemplares similares
-
Resistance to RAF inhibitors revisited
por: Hartsough, Edward, et al.
Publicado: (2013) -
NFκB-regulation of c-FLIP promotes TNFα-mediated RAF inhibitor resistance in melanoma
por: Shao, Yongping, et al.
Publicado: (2015) -
The broad stroke of Hsp90 inhibitors: painting over the RAF inhibitor paradox
por: Vido, Michael, et al.
Publicado: (2015) -
Adaptive up-regulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells
por: Basile, Kevin J., et al.
Publicado: (2011) -
Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A – C-Raf
por: Blair, Connor M., et al.
Publicado: (2019)